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Abstract
Purpose:  To  evaluate  long-term  keratoconus  stability  after  corneal  crosslinking  (CXL)  with
riboﬂavin.
Methods: In  this  prospective  study,  57  eyes  of  55  patients  with  progressive  keratoconus,  con-
secutively  treated  with  ultraviolet  A  (UVA)  --  riboﬂavin  CXL,  were  examined  with  the  corneal
topographer  Pentacam,  the  biometer  IOLMaster  and  the  analyzer  of  corneal  biomechanics  Ocu-
lar Response  Analyzer  before  and  during  a  24  months  follow-up  after  CXL.
Results: Twenty-four  months  after  CXL,  there  was  a  signiﬁcant  improvement  in  best  corrected
visual acuity  (BCVA)  (P  <  0.01),  a  signiﬁcant  decrease  in  corneal  thinnest  point  (CTP),  keratom-
etry readings  at  the  keratoconus  apex  (K  max),  and  corneal  volume  (CV)  (P  <  0.01),  and  a
signiﬁcant  increase  in  axial  eye  length  (AL)  (P  =  0.01).  No  signiﬁcant  changes  in  anterior  chamber
volume (ACV)  and  depth  (ACD),  (P  =  0.8),  corneal  hysteresis  (CH)  (P  =  0.16)  and  corneal  resis-
tance factor  (CRF)  (P  =  0.06)  were  found.  However,  in  the  subgroup  of  patients  with  decreased
K max  readings  24  months  after  treatment,  both  CH  and  CRF  showed  a  signiﬁcant  reduction
(P <  0.01).
Conclusion:  In  the  ﬁrst  month  after  the  procedure,  CXL  induces  a  reduction  in  corneal  vol-
ume. During  the  24  months  follow-up  the  cornea  tends  to  recover  its  original  volume  with  a
persistence  of  the  CXL  efﬁcacy.
© 2013  Spanish  General  Council  of  Optometry.  Published  by  Elsevier  España,  S.L.U.  All  rights
reserved.∗ Corresponding author at: Department of Medicine and Surgery, University of Salerno, via Salvador Allende, 84081 Baronissi, Salerno,
taly.
E-mail address: nrosa@unisa.it (N. Rosa).
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888-4296/© 2013 Spanish General Council of Optometry. Published by Elsevier España, S.L.U. All rights reserved.
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Resultados  A  Largo  Plazo  Del  Cross-Linking  Corneal  del  Colágeno  En  El  Queratocono
Progresivo
Resumen
Objetivo:  Evaluar  la  estabilidad  del  queratocono  a  largo  plazo  tras  cross-linking  corneal  (CXL)
con riboﬂavina.
Métodos:  En  este  estudio  prospectivo,  se  examinaron  57  ojos  de  55  pacientes  con  queratocono
progresivo,  tratados  consecutivamente  con  UVA-CXL  con  riboﬂavina  utilizando  el  topógrafo
corneal  Pentacam,  el  biómetro  IOLMaster  y  el  analizar  de  la  biomecánica  corneal  ‘‘Ocular
Response Analyzer’’  preoperatoriamente  y  a  los  24  meses  de  haberse  realizado  el  CXL.
Resultados:  A  los  veinticuatro  meses  del  CXL,  se  produjo  una  mejora  considerable  de  la  agudeza
visual mejor  corregida  (BCVA)  (p  <  0.01),  un  importante  decremento  del  punto  más  ﬁno  de  la
córnea (CTP),  de  las  medidas  queratométricas  en  el  vértice  del  queratocono  (K  max),  y  del
volumen de  la  córnea  (VC)  (p  <  0.01),  y  un  incremento  signiﬁcativo  de  la  longitud  axial  del  ojo
(LA) (p  =  0.01).  No  se  produjeron  cambios  signiﬁcativos  en  el  volumen  de  la  cámara  anterior
(VCA) ni  en  la  profundidad  de  la  misma  (PCA),  (p  =  0.8),  histéresis  de  la  córnea  (HC)  (p  =  0.16)
y factor  de  resistencia  de  la  córnea  (FRC)  (p  =  0.06).  Sin  embargo,  en  el  subgrupo  de  pacientes
con disminución  de  los  valores  de  K  max,  a  los  24  meses  del  tratamiento,  tanto  la  HC  como  la
FRC mostraron  una  reducción  considerable  (p  <  0.01).
Conclusión:  Durante  el  primer  mes  tras  la  intervención,  el  CXL  induce  una  reducción  del  vol-
umen de  la  córnea.  Durante  los  24  meses  de  seguimiento,  la  córnea  tiende  a  recuperar  su
volumen original,  persistiendo  la  eﬁcacia  del  CXL.
© 2013  Spanish  General  Council  of  Optometry.  Publicado  por  Elsevier  España,  S.L.U.  Todos  los
derechos reservados.
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diameter  area.  To  allow  sufﬁcient  saturation  of  the  stroma,Introduction
Keratoconus  is  a  corneal  ectasia  resulting  from  non-
inﬂammatory,  progressive  thinning  of  the  corneal  stroma.1
Initial  management  is  based  on  refractive  correction  with
spectacles  and  contact  lenses  or  intrastromal  corneal  ring
segments,  but  further  ectatic  progression  may  lead  to
corneal  transplantation  in  10--20%  of  the  patients.2 Corneal
collagen  crosslinking  (CXL)  with  riboﬂavin  and  ultravio-
let  A  (UVA)  has  been  used  in  several  in  vitro  studies3--10
in  the  attempt  to  enhance  corneal  biomechanical  resis-
tance  by  an  increase  in  collagen  ﬁber  diameters.11,12 As  the
main  keratoconus  characteristic  is  a  reduced  biomechani-
cal  corneal  strength,13 CXL  was  recently  proposed  to  halt  its
progression.12 In  this  study  we  report  the  clinical  results  of
CXL  treatment  in  patients  with  a  progressive  keratoconus.
Methods
Fifty-seven  eyes  of  55  patients  (39  men)  with  a  mean  age  of
22.5  ±  5  years  (range  from  11  to  35)  with  progressive  kera-
toconus,  documented  by  refraction  and  corneal  topography
in  the  last  6  months,  and  deﬁned  as  a  recent  keratomet-
ric  increase  and/or  pachymetric  decrease,  were  evaluated.
In  particular,  keratoconus  was  considered  to  be  progressive
if,  during  a  12  months’  follow-up,  there  was  an  increase
≥1  diopter  (D)  in  the  steepest  simulated  keratometry  value
derived  from  computerized  videokeratography  or  in  the
steepest  meridian  measured  by  manual  keratometry,  or  an
increase  in  astigmatism  as  determined  by  manifest  sub-
jective  refraction  ≥1.0  D,  with  subjective  deterioration  in
vision.
R
a
3
yPatients  with  a  history  of  previous  corneal  surgery,  sys-
emic  autoimmune  diseases,  diabetes,  evidence  of  severe
ry  eye,  corneal  scars  and  corneal  thickness  less  than  400  m
ere  excluded  from  the  study.  After  the  nature  and  aim  of
he  study  had  been  fully  explained,  a written  informed  con-
ent  was  obtained  from  each  patient.  The  study  and  data
ollection  were  carried  out  in  adherence  to  the  tenets  of
he  Declaration  of  Helsinki.
All  patients  underwent  a  complete  preoperative  oph-
halmologic  examination  including:  measurement  of  best-
orrected  visual  acuity  (BCVA)  in  decimal  scale;  slit  lamp  and
undus  examination;  corneal  evaluation,  including  corneal
olume  measurements,  by  a  Scheimpﬂug  imaging  device
Oculus  Pentacam,  Optikgerate  GmbH,  Wetzlar,  Germany);
xial  length  (AL)  measurement  with  an  IOLMaster  (Carl  Zeiss
editec,  Jena,  Germany);  and  evaluation  of  the  biomechan-
cal  properties  of  the  cornea,  corneal  hysteresis  (CH)  and
orneal  resistance  factor  (CRF),  with  the  Ocular  Response
nalyzer  (Reichert  Technologies,  Depew,  USA).
All  patients  were  treated  with  UVA--riboﬂavin  CXL  under
septic  conditions  using  topical  preoperative  anesthesia
ith  oxybuprocaine  hydrochloride  0.4%  (Novesina,  Novar-
is  Farma)  eye  drops.  Before  the  procedure,  2%  pilocarpine
Pilocarpina,  Farmigea)  eye  drops  were  instilled  in  the  eye
o  be  treated.  Each  patient  was  draped,  the  ocular  sur-
ace  was  rinsed  with  Balanced  saline  solution  (BSS)  and  a
id  speculum  was  inserted.  To  ensure  that  the  riboﬂavin
enetrated  the  stroma  and  to  achieve  a high  level  of  UVA
bsorption,  the  epithelial  tissue  was  removed  in  a  9.0  mmiboﬂavin  0.1%  in  20%  dextran  solution  (Ricrolin,  Sooft)  was
pplied  to  the  cornea  30  min  before  the  irradiation,  every
 min.  A  calibrated  UV  power  meter  (UV  LIGHT  meter  model
k-34uv,  Lutron  electronic,  Coopersburg,  USA)  was  used  to
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ontrol  the  desired  levels  of  irradiance  before  each  treat-
ent.  After  that,  an  8.0  mm  diameter  of  the  central  cornea
as  irradiated  with  the  Vega  C.B.M.  X-linker  (C.S.O.  Firenze)
sing  standard  parameters  (UVA  365  nm,  3  mW/cm2).  Dur-
ng  the  30  min  irradiation,  drops  of  riboﬂavin  solution  were
pplied  to  the  cornea  every  2--3  min  to  maintain  the  nec-
ssary  concentration  of  riboﬂavin  and  to  prevent  corneal
rying.  The  treatment  centration  was  controlled  by  the  sur-
eon.  At  the  end  of  the  procedure,  the  eye  surface  was
ashed  with  BSS,  and  cyclopentolate  (Ciclolux  10  mg/mL,
llergan)  and  oﬂoxacin  (Exocin  3  mg/mL,  Allergan)  eye  drops
ere  administered  and  afterwards  a  soft  bandage  contact
ens  was  applied.  Oﬂoxacin  drops  and  artiﬁcial  tears  were
iven  4  times  a  day  until  complete  reepithelialization.  After
he  contact  lens  was  removed,  steroid  eye  drops  (Dexamono
 mg/mL,  Thea)  were  used  in  a  tapered  dose  over  4  weeks
nd  artiﬁcial  tears  were  continued  4  times  a  day  for  the  same
eriod.  Statistical  analysis  was  performed  using  the  paired
tudent’s  t test.  P  <  0.01  was  considered  to  be  statistically
igniﬁcant.
We  certify  that  all  applicable  institutional  and  govern-
ental  regulations  concerning  the  ethical  use  of  human
olunteers/animals  were  followed  during  this  research.
esults
CVA,  corneal  thinnest  point  (CTP),  keratometry  readings
t  the  keratoconus  apex  (K  max),  AL,  corneal  volume  (CV),
nterior  chamber  volume  (ACV),  anterior  chamber  depth
ACD),  and  CH  and  CRF  before  treatment  and  during  the
ollow-up  are  shown  in  Table  1.  In  Figs.  1--3  the  differ-
nces  in  CTP  (Fig.  1),  K  max  (Fig.  2) and  AL  (Fig.  3)
ave  been  divided  in  3  groups:  stable,  increased,  and
ecreased.
Table  2  shows  the  changes  in  CH  and  CRF  before  and
4  months  after  treatment  in  patients  with  stability  and
ecrease  in  K  max  readings,  respectively.
These  results  indicate  that  24  months  after  CXL,  there
as  a  signiﬁcant  improvement  in  BCVA  (P  <  0.01),  a  sig-
iﬁcant  decrease  in  CTP,  K  max,  and  CV  (P  <  0.01),and
 signiﬁcant  increase  in  AL  (P  =  0.01).  Concerning  the
L  difference,  we  divided  the  patients  into  two  groups:
ediatric  patients  (6  eyes)  and  adult  patients  (24
yes)  to  check  if  the  increase  in  the  axial  length
ould  be  due  to  an  ocular  growth.  In  both  cases
he  Wilcoxon  rank  test  showed  a  signiﬁcant  increase
P  <  0.05).
No signiﬁcant  changes  in  ACV  and  ACD,  (P  =  0.8),  CH
P  =  0.16)  and  CRF  (P  =  0.06)  were  found.  However,  in  the
ubgroup  of  patients  with  decreased  K  max  readings  24
onths  after  treatment,  both  CH  and  CRF  showed  a signiﬁ-
ant  reduction  (P  <  0.01).
If  however,  we  observe  the  subgroup  of  patients,  in  which
 reduction  of  CH  and  CRF  was  found  at  24  months  follow-
p,  the  mean  difference  in  K  max  value  was  −1.21  ±  2.67 (range  +1.4  to  −7.2  D);  the  mean  difference  in  CTP  was
26.63  ±  25.83  m  (range  +16  to  −56  m);  the  mean  differ-
nce  in  CV  was  −0.91  ±  0.71  m3 (range  +0.4  to  −1.8  m3),
onﬁrming  the  previous  results.
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everal  studies  have  been  published  reporting  the  clinical
ata  after  CXL,  but  only  few  of  them  presented  a  long
ollow-up  and  some  of  them  evaluated  a  small  number  of
atients.14--18
Raiskup-Wolf  et  al.14 found  in  66  eyes  that  in  most  of
hem  there  was  an  improvement  in  BCVA,  astigmatism  and
 readings  with  a  non-signiﬁcant  change  in  central  corneal
hickness  (CCT)  at  1  year  and  an  increase  after  24  months.
inciguerra  et  al.,15 in  40  eyes  of  40  pediatric  patients  with
rogressive  keratoconus  found  a  signiﬁcant  improvement  in
ncorrected  visual  acuity  (UCVA)  and  BCVA  with  a  statis-
ically  signiﬁcant  reduction  in  mean  spherical  equivalent
nd  a  ﬂattening  effect  of  CXL  on  the  keratoconic  cornea.
oreover,  they  found  no  statistically  signiﬁcant  difference
n  pupil  center  pachymetry,  thinnest  point,  corneal  volume,
nterior  chamber  volume  and  anterior  chamber  depth  com-
ared  to  preoperative  data.
Vinciguerra  et  al.,  in  another  paper,16 found  similar
esults  in  28  eyes  with  keratoconus,  except  for  the  total
orneal  volume,  which  decreased  (P  =  0.045)  at  12  months,
ith  a  slight  increase  24  months  after  treatment  (P  =  0.06
ompared  with  the  12-month  values)  and  for  the  corneal
achymetry  at  the  thinnest  point,  which  decreased  from
aseline  to  1  year  after  CXL  (P  =  0.04)  and  increased  to
chieve  recovery  24  months  postoperatively  (P  =  0.71).  Ante-
ior  chamber  volume,  and  anterior  and  posterior  elevation
id  not  change  signiﬁcantly  during  the  24-months  follow-up,
ut  anterior  chamber  depth  decreased  24  months  postopera-
ively  with  a  statistically  signiﬁcant  difference.  Caporossi
t  al.,17 in  44  patients  with  keratoconus  between  10  and  40
ears  old,  with  a  minimum  follow-up  of  48  months,  found  an
mprovement  in  UCVA  and  BCVA  and  a  reduction  in  mean  K
eadings  with  a  hyperopic  shift,  without  statistically  signif-
cant  differences  in  central  corneal  thickness,  measured  by
S  pachymetry,  over  the  third  month  of  follow-up.  Goldich
t  al.,18 in  14  eyes  treated  with  collagen  crosslinking  for
rogressive  keratoconus,  found  a  signiﬁcant  improvement  in
CVA,  in  steepest-meridian  keratometry,  in  the  mean  cylin-
er,  with  a signiﬁcant  elongation  of  the  eyes,  whereas  no
igniﬁcant  changes  in  mean  simulated  keratometry,  mini-
al  corneal  thickness,  endothelial  cell  density  or  foveal
hickness  were  observed.  Our  data  show  that  there  was  a
igniﬁcant  improvement  in  BCVA,  with  a  relative  stability  in
CV  and  in  the  values  of  sphere  and  cylinder,  and  a  decrease
f  the  K  max  values,  in  agreement  with  previous  published
apers.  Concerning  the  corneal  thickness19 and  the  corneal
olume,  our  ﬁndings  of  a  statistically  signiﬁcant  decrease  1
onth  after  treatment,  that  tend  to  increase  during  the  24
onths  follow-up,  without  reaching  the  preoperative  val-
es,  could  be  explained  by  previous  in  vivo  ﬁndings  showing
hat,  6  months  after  CXL  treatment,  stromal  keratocyte
epopulation  was  complete  and  was  accompanied  by  the
isappearance  of  stromal  edema.20,21 Another  explanation
ould  be  the  presence  of  corneal  edema  in  the  ﬁrst  months,
ausing  artifacts  in  CCT  measurements.  Regarding  the  AL,  1
onth  after  surgery,  the  treated  eyes  showed  a statisticallyigniﬁcant  elongation  compared  to  the  preoperative  data,
hich  remained  stable  during  the  following  months,  simi-
arly  to  that  reported  by  Goldich  et  al.18 Our  study  shows  an
L  increase,  associated  with  the  stability  of  the  ACV  and  ACD
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Table  1  Comparison  in  best  corrected  visual  acuity  (BCVA)  in  decimals,  Sphere  and  Cylinder,  corneal  thinnest  point  (CTP),
keratometry  readings  at  the  keratoconus  apex  (K  max),  axial  eye  length  (AL),  corneal  volume  (CV),  anterior  chamber  volume
(ACV), anterior  chamber  depth  (ACD),  corneal  hysteresis  (CH)  and  corneal  resistance  factor  (CRF)  before  treatment  and  during
the 24  months  follow-up  (mean  ±  SD,  and  range).
Pre  op.  1  Month  3  Months  6  Months  12  Months  24  Months
BCVA  0.56  ±  0.26
0.1  to  1
0.52  ±  0.24
0.1  to  1
P  =  0.02a
0.59  ±  0.25
0.1  to  1
P =  0.05a
0.61  ±  0.26
0.1  to  1
P =  0.6a
0.69  ±  0.25
0.3  to  1
P =  0.003a
0.81  ±  0.24
0.2  to  1
P <  0.01a
P  <  0.01b
Sph  (D)  0.07  ±  2.24
−6  to  +5
0.13  ±  2.29
−6  to  +4.5
P  =  0.1a
−0.01  ±  2.64
−6  to  +6
P  =  0.4a
−0.23  ±  2.19
−6  to  +4.5
P  =  0.9a
0.66  ±  2.15
−4  to  +6
P  =  0.06a
0.14  ±  2.12
−5  to  +5
P  =  0.08a P  =  0.7b
Cyl  (D)  −3.18  ±  1.54
−8  to  −0.5
−3.02  ±  1.38
−6  to  −0.5
P  =  0.7a
−3.26  ±  1.71
−8  to  −0.5
P  =  0.8a
−3.07  ±  1.68
−8  to  0
P  =  0.1a
−3.44  ±  1.26
−6  to  −1
P  =  0.19a
−2.8  ±  2.05
−8 to  +1
P  <  0.01a
P  <  0.3b
CTP  (m)  458.4  ±  30.5
400  to  517
418.2  ±  38.6
348  to  502
P <  0.01a
415.3  ±  33.3
358  to  482
P =  0.06a
422.9  ±  44.7
340  to  576
P =  0.17a
441.1  ±  31.2
366  to  499
P =  0.38a
436.2  ±  38.1
332  to  516
P=  0.45a
P  <  0.01b
P  <  0.01c
K  max  (D)  58.04  ±  4.92
47.4  to  70.6
58.77  ±  4.79
47.6  to  72.5
P <  0.01a
58.27  ±  4.85
47  to  72.2
P  <  0.01a
56.75  ±  5.2
46.7  to  73.2
P =  0.01a
56.31  ±  5.71
48.7  to  73.1
P =  0.09a
55.82  ±  5.37
46.7  to  73.7
P <  0.01a
P  <  0.01b
AL  (mm)  23.92  ±  0.96
22.2  to  26.22
24.09  ±  0.92
22.31  to  26.25
P <  0.01a
23.99  ±  0.99
22.14  to  26.32
P =  0.79a
24.03  ±  0.99
22.29  to  26.43
P =  0.51a
23.79  ±  0.96
22.3  to  25.35
P =  0.37a
24.09  ±  0.96
22.31  to  26.23
P  =  0.06a
P  =  0.01b
P  =  0.04c
CV  (mm3)  56.9  ±  3
51.1  to  64.5
54.7  ±  3.2
48.8  to  62.6
P <  0.01a
55.7  ±  3.4
49.6  to  63.1
P <  0.01a
55.8  ±  3.5
43.3  to  62.2
P =  0.8a
57.4  ±  3.2
50.2  to  63.7
P =  0.5a
56.6  ±  3
50.4  to  64.1
P =  0.4a
P  <  0.01b
P  <  0.01c
ACV  (mm3)  226.9  ±  33.9
155  to  297
230.6  ±  38.3
155  to  313
P =  0.1a
235.5  ±  32.7
175  to  298
P =  0.6a
230.9  ±  37.1
161  to  304
P =  0.5a
223  ±  34.7
152  to  289
P =  0.6a
226.8  ±  37.8
145  to  291
P =  0.8a
P  =  0.3b
ACD  (mm)  3.99  ±  0.3
3.43  to  4.72
4.0  ±  0.33
3.35  to  4.79
P =  0.96a
4.03  ±  0.31
3.41  to  4.79
P =  0.01a
3.99  ±  0.32
3.41to  4.72
P =  0.44a
3.94  ±  0.32
3.41  to  4.52
P =  0.71a
3.94  ±  0.35
3.2  to  4.70
P =  0.59a
P  <  0.01b
CH  (mmHg)  8.0  ±  1.2
5.4  to  10.4
7.5  ±  1.1
5to  10.1
P  =  0.07a
7.4  ±  0.9
5.8  to  9.2
P =  0.3a
7.2  ±  1.3
5.4  to  9.1
P =  0.2a
7.7  ±  1.1
5.5  to  9.5
P =  0.02a
7.8  ±  1.3
5.9  to  11
P =  0.9a
P  =  0.16b
CRF  (mmHg)  6.6  ±  1.4
3.9  to  9.5
6.9  ±  1.2
4.6  to  9.0
P  =  0.01a
6.2  ±  1.2
3.8  to  8.3
P =  0.01a
6.1  ±  1.8
3.8  to  9.2
P =  0.3a
6.4  ±  1.2
4.3  to  8.1
P =  0.4a
6.3  ±  1.3
3.7  to  8.8
P =  0.8a
P  =  0.06b
a T test evaluation with immediately previous follow-up.
b -up.T test evaluation between pre-operative and 24 months follow
c T test evaluation between 1 month and 24 months follow-up.during  the  24  months  follow  up.  This  is  an  important  ﬁnding,
as  it  supports  the  theory  that  this  increase  is  due  to  an  elon-
gation  of  the  posterior  segment  of  the  eye,  unrelated  to  the
treatment.  When  we  divide  the  patients  into  two  groups,
a
i
i
sdults  and  pediatrics,  in  both  cases  we  found  a signiﬁcant
ncrease.  This  ﬁnding  does  not  prove  that  the  elongation
s  unrelated  to  eye  growth,  as  it  has  been  shown  that  in
ome  individuals  the  eye  elongation  can  also  be  present  also
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Figure  1  Percentage  of  eyes  with  stability,  increase  or  decrease  in  corneal  thinnest  point  (CTP)  values.
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eFigure  2  Percentage  of  eyes  with  stability,  increase  or  
n  adult  age.22--24 On  the  other  hand,  the  increase  in  AL,
ith  corneal  ﬂattening,  (decrease  in  K  max  values),  could
xplain  the  stability  in  refraction  during  the  entire  follow-up
xamination.
a
e
aease  in  keratometry  at  keratoconus  apex  (K  max)  values.
Concerning  the  biomechanical  parameters,  our  data  on
ll  the  examined  population,  showing  no  statistical  differ-
nces  between  preoperative  and  24  months  follow-up  data,
gree  with  the  other  papers  dealing  with  this  issue.25--29
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Figure  3  Percentage  of  eyes  with  stability,  increase  or  decrease  in  axial  eye  length  (AL)  values.
Table  2  Changes  in  corneal  hysteresis  (CH)  and  corneal  resistance  factor  (CRF)  in  the  group  of  patients  with  stability  (GROUP
1) and  in  the  one  with  decrease  (GROUP  2)  in  keratometry  readings  at  the  keratoconus  apex  (K  max)  before  treatment  and  at
24 months  follow-up  (mean  ±  SD,  and  range).
GROUP  1  GROUP  2
Pre  op.  24  Months  Pre  op.  24  Months
CH  (mmHg)  8.1  ±  1.6
6.1  to  10.4
8.7  ±  1.6
6.9  to  11.0
P  =  0.08
8.2  ±  1.0
6.5  to  9.6
7.6  ±  1.1
5.9  to  9.4
P  <  0.01
CRF (mmHg)  6.5  ±  1.7 6.8  ±  1.6
.8
6.8  ±  1.0 6.1  ±  1.2
t
p
w
e
c
d
n
l
m
p
p
f4.3  to  8.8 5.0  to  8
P  =  0.87
However,  when  we  analyze  only  the  subgroup  of  eyes  with
improvement  (decrease)  in  K  max  readings  at  24  months
follow-up,  we  observe  a  statistically  signiﬁcant  reduction
of  CH  and  CRF  (Table  2).  This  ﬁnding  is  conﬁrmed  when
we  analyze  the  data  of  patients  with  reduction  in  CH  and
CRF  at  24  months  follow-up,  as  in  this  subgroup  of  patients
there  is  a  mean  reduction  in  K  max  readings,  in  CV  and  in
CTP.
The  correlation  between  CH  and  CRF  with  corneal  thick-
ness  could  explain  this  ﬁnding.28,29
Another  explanation  may  be  that  CXL  produces  a stabi-
lization  of  the  keratoconus  evolution  with  ultra-structural
changes  of  the  cornea  without  affecting  the  corneal  vis-
coelasticity.
One  limitation  of  this  study  might  be  the  lack  of  data
regarding  the  endothelial  cells.  The  reason  why  we  did  not
evaluate  the  cell  density  was  that  the  safety  of  this  kind  of
F
N4.6  to  8.3 3.7  to  8.0
P  <  0.01
reatment  was  not  the  aim  of  this  study.  However,  a  recently
ublished  paper,  investigating  the  effects  of  CXL  in  eyes
ith  progressive  keratoconus,  showed  no  signiﬁcant  differ-
nce  in  endothelial  cell  density  at  any  follow-up  time  when
ompared  with  baseline  data  and,  similarly,  no  signiﬁcant
ifferences  with  the  control  group.30
In  conclusion,  our  data  seem  to  conﬁrm  the  effective-
ess  of  the  treatment  that  induces  shrinkage  of  the  corneal
amellae,  with  a  reduction  in  corneal  volume,  in  the  ﬁrst
onth  after  the  procedure,  and  a  tendency  to  recover  to
reoperative  values  during  the  following  period,  but  with
ersistence  of  the  efﬁcacy  of  the  treatment  at  24  months
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